Compare DELL & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DELL | AZN |
|---|---|---|
| Founded | 1984 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.7B | 316.4B |
| IPO Year | 2013 | N/A |
| Metric | DELL | AZN |
|---|---|---|
| Price | $404.27 | $178.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $181.63 | N/A |
| AVG Volume (30 Days) | ★ 9.8M | 1.9M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | 1.23% | ★ 1.73% |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 5.24 | N/A |
| Revenue | ★ $113,538,000,000.00 | N/A |
| Revenue This Year | $26.19 | $10.34 |
| Revenue Next Year | $8.60 | $6.43 |
| P/E Ratio | $78.04 | ★ $31.91 |
| Revenue Growth | ★ 18.80 | N/A |
| 52 Week Low | $110.22 | $68.62 |
| 52 Week High | $469.47 | $212.71 |
| Indicator | DELL | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 43.57 |
| Support Level | $126.13 | $174.60 |
| Resistance Level | $469.47 | $191.50 |
| Average True Range (ATR) | 28.95 | 3.13 |
| MACD | -3.29 | -0.18 |
| Stochastic Oscillator | 60.94 | 32.80 |
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.